Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib temsirolimus + pegylated liposomal doxorubicin in advanced or recurrent breast, endometrial, and ovarian cancer
NL-OMON33331Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2009
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Trial of temsirolimus and pegylated liposomal doxorubicin, sponsored by Radboud University Medical Center. Started Jun 2009; status: recruiting.
02
Drugs
temsirolimuspegylated liposomal doxorubicin
Beyond the preview
Go deeper on NL-OMON33331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33331.